Alzheimer Europe's December 2025 newsletter brings you the latest news on developments in the dementia field, across Europe and beyond.

Summaries of a few of our top stories appear below.

Our monthly newsletter reaches almost 11,000 people, who have an interest in dementia, from across Europe and beyond.

We are always happy to receive feedback, or suggestions regarding news items to share.

On 2 December 2025, Alzheimer Europe held a lunch debate at the European Parliament in Brussels (Belgium), exploring the future of dementia research in Europe. The event was attended by national Alzheimer associations, civil society representatives, industry partners and policymakers, including MEPs. Our hosts were Co-Chairs of the European Alzheimer’s Alliance, Tilly Metz MEP (Luxembourg) and Sirpa Pietikäinen MEP (Finland). 

On 2 December 2025, at a special award ceremony in Brussels (Belgium), Photographer Alex Kornhuber was announced as the winner of the 2025 Anti-Stigma-Award, for his series of portraits “Keepsake Chronicles”. Huge congratulations to him, and to runners-up Desideria Care e.V. (Germany) for their open-air photo exhibition “Seeing Dementia in a New Light”, and Hungarian photographer Bálint Szajki for his deeply intimate photo essay, “In Sickness and in Health”. Congratulations, also, to all six entries that received “honourable “mentions”. 

The Clinical Trials on Alzheimer’s Disease (CTAD) conference 2025 took place in San Diego (USA), from 1 to 4 December. We have selected a few research highlights from the event. Check them out!

On 9 December, Alzheimer Europe launched the Dementia in Europe Yearbook 2025, which highlights programmes and resources relating to transport and access to cultural life, recreation, leisure and sport. These topics are vital components in the lives of people with dementia and their carers, which help them to stay actively engaged in the communities in which they live. 

The Committee for Medicinal Products for Human use (CHMP) of the European Medicines Agency has issued a negative opinion on the marketing authorisation application for blarcamesine for the treatment of early Alzheimer’s disease. We hope that the re-examination request lodged by Anavex will provide additional evidence for the CHMP to reconsider its position.

Two full-time, permanent positions have opened up at Alzheimer Europe, for a Project Administrator and an Administrative and Conference Assistant. Please see our job advert for more details about how and when to apply. We look forward to hearing from you!